Newsflash Issue 475

Jun 29, 2009
1,464 views

POSSIBLE LINK BETWEEN INSULIN GLARGINE AND CANCER QUESTIONED – MORE RESEARCH REQUIRED

Experts stress patients should not stop using insulin and consult their doctor if concerned. See This Week’s Item 1

Takeda’s Diabetes Drug Alogliptin Rejected by FDA

Asia’s biggest drugmaker, Takeda, failed to gain U.S. regulatory approval to market its new diabetes drug alogliptin because of insufficient data. The U.S. Food and Drug Administration issued a so-called complete-response letter saying the company must provide more data on cardiovascular risks. More information in next week’s issue.